Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02858869 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02858869 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 25 participants.
The verdict
NCT02858869, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Giving pembrolizumab together with stereotactic radiosurgery may be a better treatment for patients with melanoma or non-small cell lung cancer that has spread to the brain.
Interventions
- BIOLOGICAL Pembrolizumab
- RADIATION Stereotactic Radiosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-10-04 |
| Est. Completion | 2023-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02858869
The ClinicalTrials.gov registry entry for NCT02858869 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02858869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02858869 about?
NCT02858869 is a clinical study titled "Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases". This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow an...
What is the current status of trial NCT02858869?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2016-10-04. Estimated completion is 2023-10-28.
What interventions are being tested in trial NCT02858869?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Stereotactic Radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT02858869?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.